Connect with us

MDMA

A Look at Small Cap Psychedelic Companies: Part 2

The article A Look at Small Cap Psychedelic Companies: Part 2 was originally published on Microdose.

The psychedelic medicine industry is growing. There’s…

Published

on

The article A Look at Small Cap Psychedelic Companies: Part 2 was originally published on Microdose.

The psychedelic medicine industry is growing. There’s rapid expansion in both the number of firms joining the industry and the amount of daily news and major announcements.

Yet with bigger names hogging the limelight, and only so much time in the day, it’s easy for newer companies to get lost in the shuffle. Yet these small cap firms offer interesting potential opportunities for investors, so to help you stay informed we’ve put together a list of some of the top small cap companies.

Awakn Life Sciences

NEO: AWKN
Market Cap: $48.9 million

Awakn is a UK-based psychedelics company focused on the treatment of addiction, with drug research underway on ketamine and MDMA for Alcohol Use Disorder. Awakn also has a division dedicated to in-person clinics (Awakn Clinics), with plans to open locations in 2021, and a digital therapeutics division (Awakn Digital). The company plans to deliver psychedelic therapies for addiction in clinics in the UK and Europe, as well as generating revenue through licensing partnerships.

Although relatively new to the space, Awakn is already planning a Phase 2b study. Taking place in the UK, this trial will be a double-blind, placebo-controlled clinical trial designed to investigate MDMA as a treatment for Alcohol Use Disorder. Once underway, Awakn will be one of the most advanced firms in MDMA clinical trials.

Wesana Health

CSE: WESA
Market Cap: $34.3 million

Founded by ex-NHL hockey player Daniel Carcillo, and backed by boxing legend Mike Tyson, Wesana Health is a life sciences company focused on psychedelic therapies to treat traumatic brain injury (TBI). Building on clinical research and academic partnerships, Wesana Health is working to help patients overcome neurological and mental health ailments caused by trauma.

Wesana recently acquired Psychedelitech Inc. (PsyTech), giving Wesana access to several new development channels. Wesana Clinics is a chain of mental health clinics offering ketamine therapy; Wesana Solutions is a medical-grade SaaS platform developing clinical protocols to help mental healthcare outcomes; and PsyTech Connect is a community and annual conference of thousands of psychedelic professionals.

Wesana has also started a partnership with renowned non-profit MAPS to fund and partake in clinical development of treatments for TBI using MDMA.

CURE Pharmaceutical

OTC: CURR
Market Cap: $45.2 million

CURE is building a vertically-integrated model featuring drug and delivery technologies along with manufacturing capabilities. Currently running a 25,000 square foot, FDA-registered, cGMP-certified manufacturing facility, CURE is working to partner with pharmaceutical and wellness companies for white-label production. The company also holds a DEA Schedule 1 license.

On the development side, CURE is developing a variety of patented drug delivery platforms designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. The company has launched a clinical development program for psychedelic compounds, utilizing its patented oral film platform for precision dosing, hoping to optimize the absorption and metabolism of psychedelic molecules.

Revitalist Lifestyle and Wellness

CSE: CALM
Market Cap: $33.13 million

Revitalist Lifestyle and Wellness is headquartered in Knoxville, Tennessee. Focused on delivering in-person treatment and ketamine-infusion, the company is working to be a leader in innovative patient treatments.

Since opening their first clinic in 2018, Revitalist has provided over 7,000 infusions for patients suffering from treatment-resistant conditions. The company currently runs five clinics across the United States and has ambitious clinic expansion plans. Revitalist is divided into 4 pillars: The Zone (Athlete focussed), General Public, Adolescent Mental Health, and Helping Heroes (Veteran Advocacy Program). The company is also working to solve future accessibility and cost issues around insurance coverage, and the company has already secured relationships with federal and commercial insurance providers.

Nexstage Therapeutics

TLV: NXTG
Market Cap: N/A

Nextage Therapeutics is an Israel-based pharmaceutical company developing therapeutic data-driven products, as well as next-generation cannabinoid products.

Nextage’s proprietary Brain Targeting Liposome System (BTLS) technology has been the company’s main entry into the psychedelic space. This drug delivery system allows for targeted delivery of active pharmaceutical ingredients (APIs), reducing potential risks and increasing efficacy.

Nextage has signed an exclusive agreement with industry leader MindMed to use their BTLS tech for the delivery of psychedelic medicines. Additionally, Nextage’s parent company IMIO Life recently sold a minority stake in its company to Canadian psychedelic startup PurMinds BioPharma, a move that will bring Nextage further into psychedelic medicine development.

Trading on the Tel Aviv Stock Exchange, an accurate market capitalization figure wasn’t available at the time of publication.

Interested in seeing more top small cap companies? See Microdose’s feature on other smaller-cap firms here.

Read More

Trending